New Frontiers: Procedures to Tackle Resistant Hypertension
Published: Mar 06, 2024
When medications aren't enough, innovative procedures offer new hope for those battling resistant hypertension. Explore the latest options available.
Contents
Renal Denervation: A Cutting-Edge Therapy
Renal denervation targets nerves in the kidneys to reduce blood pressure. This minimally invasive procedure can be particularly helpful for patients who don't respond well to medications. Several studies have shown its potential in lowering blood pressure, although it's not yet widely available.
Baroreflex Activation Therapy
Baroreflex Activation Therapy involves implanting a device that stimulates the carotid baroreceptors to control blood pressure. Initial trials indicate this therapy can lead to significant blood pressure reductions. However, it's still in the experimental stage and not yet approved in many countries.
Considering the Risks and Benefits
While these procedures offer hope, they come with potential risks like nerve injury or fluid retention. Careful evaluation and consultation with healthcare providers are essential. These procedures are usually considered when other treatment options have failed.
Frequently Asked Questions
It's a procedure targeting kidney nerves to lower blood pressure.
It uses a device to stimulate carotid baroreceptors, reducing blood pressure.
Yes, potential risks include nerve injury and fluid retention.
They are still experimental and not approved in all regions.
Key Takeaways
While promising, these procedures should be considered carefully alongside traditional treatments.
Explore advanced treatment options with Doctronic to manage resistant hypertension!Related Articles
References
Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022; 400:1405.
Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58:765.
Always discuss health information with your healthcare provider.